百济神州

最新新闻

• 公司公告
  Record of Investor Relations Activities of BeiGene, Ltd. (August 2026)
  SZSI · 2026/8/7
• 评级变动
  RBC Capital Maintains BeiGene(ONC.US) With Buy Rating, Maintains Target Price $450
  \u5e02\u573a\u8d44\u8baf · 2026/8/25
• 评级变动
  Barclays Maintains BeiGene(ONC.US) With Buy Rating, Raises Target Price to $415
  \u5e02\u573a\u8d44\u8baf · 2026/9/10
• 评级变动
  Truist Financial Maintains BeiGene(ONC.US) With Buy Rating, Announces Target Price $420
  \u5e02\u573a\u8d44\u8baf · 2026/10/9
• Goldman Sachs: BeiGene (ONC.US) Q2 Sales Slightly Beat Expectations; Maintains "Buy" Rating
  AASTOCKS · 2026/8/24
• UBS Group: Most Chinese biotech firms exceeded sales expectations in the first half; global R&D catalysts will be key in the second half. Top pick: BeiGene (ONC.US)
  Zhitong Finance · 2026/9/7
• 评级变动
  RBC Capital Maintains BeiGene(ONC.US) With Buy Rating, Raises Target Price to $459
  \u5e02\u573a\u8d44\u8baf · 2026/10/8
• 评级变动
  Truist Financial Maintains BeiGene(ONC.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/10/5
• 评级变动
  BeiGene (688235): Strong sales of its flagship product and continued expansion of its pipeline.
  CITIC Securities · 2026/8/9
• 公司公告
  BeiGene: U.S. Stock Market Announcement: Quarterly Report on Form 10-Q
  SZSI · 2026/8/6
• 评级变动
  J.P. Morgan Maintains BeiGene(ONC.US) With Buy Rating, Raises Target Price to $445
  \u5e02\u573a\u8d44\u8baf · 2026/10/1
• 评级变动
  Wolfe Research Maintains BeiGene(ONC.US) With Buy Rating, Raises Target Price to $370
  \u5e02\u573a\u8d44\u8baf · 2026/8/10
• 评级变动
  A Quick Look at Today's Ratings for BeiGene(ONC.US), With a Forecast Between $400 to $466
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• UBS Group: Chinese biotech firms’ H1 sales largely exceeded expectations; global R&D catalysts in H2 will be key; BeiGene is the top pick.
  AASTOCKS · 2026/9/4
• 公司公告
  BeiGene, Ltd. Investor Relations Activity Log – 20260806
  SZSI · 2026/8/7
• CLSA: Fundamentals of China's biotechnology sector remain solid; top picks are BeiGene (06160), Innovent Bio (01801), and WeLiShengBo (09887).
  Zhitong Finance · 2026/9/7
• 评级变动
  BeiGene (688235): Profit growth to remain robust in Q2 2026; full-year revenue and profit guidance raised.
  Tianfeng Securities · 2026/8/28
• The Capital Group increased its holdings in BeiGene (06160.HK) by 1.9494 million H shares, valued at approximately USD 699 million.
  \u5e02\u573a\u8d44\u8baf · 2026/9/28
• 公司公告
  BeiGene: Announcement by BeiGene, Ltd. Regarding the Convening of the 2026 Semi-Annual Results Presentation
  SZSI · 2026/8/21
• 公司公告
  BeiGene: Special Report on the Deposit and Actual Use of Funds Raised in the First Half of 2026 by BeiGene, Ltd.
  SZSI · 2026/8/27
• 评级变动
  J.P. Morgan Maintains BeiGene(ONC.US) With Buy Rating, Announces Target Price $425
  \u5e02\u573a\u8d44\u8baf · 2026/7/23
• 评级变动
  Barclays Maintains BeiGene(ONC.US) With Buy Rating, Cuts Target Price to $403
  \u5e02\u573a\u8d44\u8baf · 2026/7/14
• JPMorgan increased its holding in BeiGene (06160.HK) by 4.1197 million ordinary shares, valued at approximately HK$905 million.
  \u5e02\u573a\u8d44\u8baf · 2026/8/14
• 评级变动
  BeiGene (688235): Strong U.S. Market Performance and Efficient Advancement of Solid Tumor R&D
  China Post Securities · 2026/8/7
• 评级变动
  Morgan Stanley Maintains BeiGene(ONC.US) With Buy Rating, Maintains Target Price $395
  \u5e02\u573a\u8d44\u8baf · 2026/7/23

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。